abstract |
The invention relates to compounds of formula I: n n n n n n n n n n n n or pharmaceutically acceptable acid addition salts thereof, where; R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; n R 2 is hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II; n n n n n n n n n n n n n n n n R 3 is hydrogen or C 1 -C 3 alkyl; n R 4 is hydrogen, halo, or C 1 -C 3 alkyl; n R 5 is hydrogen or C 1 -C 3 alkyl; n R 6 is hydrogen or C 1 -C 6 alkyl; and n n is an integer from 1 to 6 inclusively. n n n n n The compounds of the present invention are useful for activating 5-HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I. |